Aspect Medical to initiate BRITE trial
This article was originally published in The Gray Sheet
Executive Summary375-patient, 9-center BRITE-MD (Biomarkers for Rapid Identification of Treatment Efficacy-Major Depression) trial begins enrollment in the U.S., with expected trial completion in June 2007. The firm's brain assessment technology, which predicts the effectiveness of antidepressants by analyzing electrical activity in the brain, will be used on patients from 21 to 75 years of age in the trial. According to Aspect, the new technology could help to reduce the number of rounds of pharmaceutical treatment a patient must endure prior to finding an efficacious antidepressant. Prior research by the firm showed that the technology predicted response to antidepressants with more than 80% accuracy (1"The Gray Sheet" Nov. 7, 2005, p. 16)...
You may also be interested in...
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.
Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.